cisapride has been researched along with Disease Models, Animal in 15 studies
Cisapride: A substituted benzamide used for its prokinetic properties. It is used in the management of gastroesophageal reflux disease, functional dyspepsia, and other disorders associated with impaired gastrointestinal motility. (Martindale The Extra Pharmacopoeia, 31st ed)
cisapride : The amide resulting from formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with cis-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-amine. It has been used (as its monohydrate or as its tartrate) for the treatment of gastro-oesophageal reflux disease and for non-ulcer dyspepsia, but its propensity to cause cardiac arrhythmias resulted in its complete withdrawal from many countries, including the U.K., and restrictions on its use elsewhere.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The pharmacological activity of AFE and pure scopoletin at the same equivalent dose present in AFE was investigated in rat on gastro-esophageal inflammatory models (acid reflux esophagitis, acute gastritis induced by ethanol and serotonin, and chronic gastric ulcer induced by acetic acid); gastric biochemical parameters and gastrointestinal motility." | 7.77 | Effects of Morinda citrifolia aqueous fruit extract and its biomarker scopoletin on reflux esophagitis and gastric ulcer in rats. ( Kasiwong, S; Mahattanadul, S; Nima, S; Phdoongsombut, N; Ratanasuwon, P; Ridtitid, W, 2011) |
| "To investigate the therapeutic effect of cisapride on gastric injury following hemorrhagic shock resuscitation." | 7.73 | Therapeutic effect of cisapride on gastric injury following hemorrhagic shock resuscitation in rats. ( Wang, ZG; Xu, Y; Zhang, LY; Zhu, PF, 2005) |
| " Gallbladder contractility, measured in vitro in response to CCK, decreased 23% in animals on the 1% cholesterol diet; cisapride restored the CCK dose-response curve to normal." | 5.29 | Cisapride improves gallbladder contractility and bile lipid composition in an animal model of gallstone disease. ( Shaffer, EA; Xu, QW, 1993) |
| " The pharmacological activity of AFE and pure scopoletin at the same equivalent dose present in AFE was investigated in rat on gastro-esophageal inflammatory models (acid reflux esophagitis, acute gastritis induced by ethanol and serotonin, and chronic gastric ulcer induced by acetic acid); gastric biochemical parameters and gastrointestinal motility." | 3.77 | Effects of Morinda citrifolia aqueous fruit extract and its biomarker scopoletin on reflux esophagitis and gastric ulcer in rats. ( Kasiwong, S; Mahattanadul, S; Nima, S; Phdoongsombut, N; Ratanasuwon, P; Ridtitid, W, 2011) |
| "To investigate the therapeutic effect of cisapride on gastric injury following hemorrhagic shock resuscitation." | 3.73 | Therapeutic effect of cisapride on gastric injury following hemorrhagic shock resuscitation in rats. ( Wang, ZG; Xu, Y; Zhang, LY; Zhu, PF, 2005) |
| "7 mM and Mg2+=1 mM), d,l-sotalol (10 and 30 microM), a class III antiarrhythmic drug, prolonged ventricular repolarization, such as QT intervals and monophasic action potential duration, and induced early after-depolarization and polymorphic ventricular tachyarrhythmia." | 3.71 | Drug-induced ventricular tachyarrhythmia in isolated rabbit hearts with atrioventricular block. ( Ito, T; Kii, Y, 2002) |
| "Constipation is one of the most common gastrointestinal disorders with a prevalence up to 16." | 2.53 | [Current Status of Translational Research on Constipation]. ( Lee, HJ; Park, KS, 2016) |
| " Cisapride (1, 3 and 10 mg/kg) caused non-significant increases in the indices of gastric emptying, with roughly bell-shaped dose-response curves." | 1.35 | Oral mitemcinal (GM-611), an erythromycin-derived prokinetic, accelerates normal and experimentally delayed gastric emptying in conscious dogs. ( Akima, M; Itoh, Z; Kamei, K; Koga, H; Omura, S; Onoma, M; Ozaki, K; Takanashi, H; Yogo, K, 2008) |
| "Pretreatment with cisapride (0." | 1.29 | Protective effect of cisapride against indomethacin-induced obstruction of the gastric mucosal hemodynamics in rats. ( Ishii, A; Karasawa, A; Kitazawa, T; Ogihara, T; Sato, N; Yokoyama, T, 1994) |
| " Gallbladder contractility, measured in vitro in response to CCK, decreased 23% in animals on the 1% cholesterol diet; cisapride restored the CCK dose-response curve to normal." | 1.29 | Cisapride improves gallbladder contractility and bile lipid composition in an animal model of gallstone disease. ( Shaffer, EA; Xu, QW, 1993) |
| "Cisapride is a "prokinetic" agent (increases gastric emptying), that may increase the splanchnic circulation and thus favourably affect gas exchange in peritoneal ventilation." | 1.29 | Peritoneal ventilation in rabbits: augmentation of gas exchange with cisapride. ( Barr, J; Bistritzer, T; Eshel, G; Gurevitch, S; Klin, B; Lahat, E; Lushkov, G; Strauss, S, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.67) | 18.7374 |
| 1990's | 5 (33.33) | 18.2507 |
| 2000's | 6 (40.00) | 29.6817 |
| 2010's | 2 (13.33) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Lee, HJ | 1 |
| Park, KS | 1 |
| Mahattanadul, S | 1 |
| Ridtitid, W | 1 |
| Nima, S | 1 |
| Phdoongsombut, N | 1 |
| Ratanasuwon, P | 1 |
| Kasiwong, S | 1 |
| Fossa, AA | 1 |
| DePasquale, MJ | 1 |
| Raunig, DL | 1 |
| Avery, MJ | 1 |
| Leishman, DJ | 1 |
| Sugiyama, A | 1 |
| Zhang, LY | 1 |
| Wang, ZG | 1 |
| Zhu, PF | 1 |
| Xu, Y | 1 |
| Shiotani, M | 1 |
| Harada, T | 1 |
| Abe, J | 1 |
| Sawada, Y | 1 |
| Hashimoto, K | 1 |
| Hamada, Y | 1 |
| Horii, I | 1 |
| Onoma, M | 1 |
| Yogo, K | 1 |
| Ozaki, K | 1 |
| Kamei, K | 1 |
| Akima, M | 1 |
| Koga, H | 1 |
| Itoh, Z | 1 |
| Omura, S | 1 |
| Takanashi, H | 1 |
| Yokoyama, T | 1 |
| Kitazawa, T | 1 |
| Ishii, A | 1 |
| Ogihara, T | 1 |
| Sato, N | 1 |
| Karasawa, A | 1 |
| Xu, QW | 1 |
| Shaffer, EA | 1 |
| Barr, J | 1 |
| Lushkov, G | 1 |
| Strauss, S | 1 |
| Gurevitch, S | 1 |
| Lahat, E | 1 |
| Bistritzer, T | 1 |
| Klin, B | 1 |
| Eshel, G | 1 |
| López, A | 1 |
| Motilva, V | 1 |
| Alarcón de la Lastra, C | 1 |
| Martín, MJ | 1 |
| La Casa, C | 1 |
| Chen, YJ | 1 |
| Lee, SH | 1 |
| Hsieh, MH | 1 |
| Hsiao, CJ | 1 |
| Yu, WC | 1 |
| Chiou, CW | 1 |
| Chen, SA | 1 |
| Kii, Y | 1 |
| Ito, T | 1 |
| Springall, RG | 1 |
| Spitz, L | 1 |
2 reviews available for cisapride and Disease Models, Animal
| Article | Year |
|---|---|
[Current Status of Translational Research on Constipation].
Topics: Animals; Cisapride; Colon; Constipation; Disease Models, Animal; Humans; Interstitial Cells of Cajal | 2016 |
[Effects of clinically available drugs on the repolarization process of the heart assessed by the in vivo canine models].
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Antipsychotic Agents; Antitubercular Agents; Cat | 2003 |
13 other studies available for cisapride and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Effects of Morinda citrifolia aqueous fruit extract and its biomarker scopoletin on reflux esophagitis and gastric ulcer in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetic Acid; Animals; Biomarkers; Cisapride; Disease Models | 2011 |
The relationship of clinical QT prolongation to outcome in the conscious dog using a beat-to-beat QT-RR interval assessment.
Topics: Animals; Anti-Arrhythmia Agents; Butylamines; Cisapride; Disease Models, Animal; Dogs; Female; Heart | 2002 |
Therapeutic effect of cisapride on gastric injury following hemorrhagic shock resuscitation in rats.
Topics: Animals; Cisapride; Disease Models, Animal; Gastric Emptying; Gastric Mucosa; Gastrointestinal Agent | 2005 |
Practical application of guinea pig telemetry system for QT evaluation.
Topics: Animals; Anti-Arrhythmia Agents; Antipsychotic Agents; Bepridil; Cisapride; Disease Models, Animal; | 2005 |
Oral mitemcinal (GM-611), an erythromycin-derived prokinetic, accelerates normal and experimentally delayed gastric emptying in conscious dogs.
Topics: Acetaminophen; Administration, Oral; Animals; Cisapride; Clonidine; Disease Models, Animal; Dogs; Do | 2008 |
Protective effect of cisapride against indomethacin-induced obstruction of the gastric mucosal hemodynamics in rats.
Topics: Animals; Cisapride; Disease Models, Animal; Drug Interactions; Gastric Mucosa; Gastrointestinal Moti | 1994 |
Cisapride improves gallbladder contractility and bile lipid composition in an animal model of gallstone disease.
Topics: Animals; Bile; Bile Acids and Salts; Carbon Radioisotopes; Cholecystokinin; Cholelithiasis; Choleste | 1993 |
Peritoneal ventilation in rabbits: augmentation of gas exchange with cisapride.
Topics: Animals; Blood Flow Velocity; Carbon Dioxide; Cisapride; Cross-Over Studies; Disease Models, Animal; | 1996 |
The role of gastric mucosal sulphydryls in the ulcer-protecting effects of cisapride.
Topics: Animals; Anti-Ulcer Agents; Cisapride; Disease Models, Animal; Ethanol; Ethylmaleimide; Gastric Muco | 1996 |
Effects of 17beta-estradiol on tachycardia-induced changes of atrial refractoriness and cisapride-induced ventricular arrhythmia.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Cisapride; Disease Models, Animal; Dogs; Dose-Re | 1999 |
Drug-induced ventricular tachyarrhythmia in isolated rabbit hearts with atrioventricular block.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Benzamides; Cisapride; Dimethyl Sulfoxide; Disea | 2002 |
The prevention of post-operative adhesions using a gastrointestinal prokinetic agent.
Topics: Administration, Cutaneous; Anastomosis, Surgical; Animals; Cisapride; Disease Models, Animal; Female | 1989 |